6,109 Results

Venetoclax for the treatment of patients with chronic lymphocytic leukemia.

Venetoclax is a potent, selective inhibitor of BCL-2, a key regulator of the intrinsic pathway of apoptosis. In preclinical studies, venetoclax bound to BCL-2 with high affinity and rapidly induced apoptosis...

Development of venetoclax for therapy of lymphoid malignancies.

B-cell lymphoma-2 (BCL-2) family dysfunction and impairment of apoptosis are common in most B-cell lymphoid malignancies. Venetoclax (Venclexta formerly ABT-199, GDC-0199) is a highly selective BCL-2 inhibitor...

Edoxaban in Atrial Fibrillation and Venous Thromboembolism-Ten Key Questions and Answers: A Practical Guide.

Edoxaban is the fourth non-vitamin K antagonist oral anticoagulant now available for clinical use in the prevention of stroke/systemic embolism in atrial fibrillation (AF) and in the treatment of venous thromboembolism (VTE) ...

Edoxaban: A direct oral anticoagulant.

Purpose: The pharmacology, pharmacokinetics, pharmacodynamics, clinical efficacy, safety, and place in therapy of edoxaban for prevention of stroke in patients with nonvalvular atrial fibrillation (AF) and ...

Recent advances of highly selective CDK4/6 inhibitors in breast cancer.

Uncontrolled cell division is the hallmark of cancers. Full understanding of cell cycle regulation would contribute to promising cancer therapies. In particular, cyclin-dependent kinases 4/6 (CDK4/6), which are pivotal ...

Progress of CDK4/6 Inhibitor Palbociclib in the Treatment of Cancer.

The cyclin-dependent kinases (CDKs) and their cyclin partners are key regulators of the cell cycle. These kinases are closely related to oncogenesis and have been proved to be attractive targets for designing novel anticancer agents

Low, fixed dose defibrotide in management of hepatic veno-occlusive disease post stem cell transplantation.

Objective/Background: Hepatic veno-occlusive disease (VOD) is well recognized potentially serious regimen-related toxicity seen after stem cell transplantation.

Eluxadoline: A Review in Diarrhoea-Predominant Irritable Bowel Syndrome.

Eluxadoline (Truberzi) is an orally administered, minimally absorbed agent that acts locally in the gastrointestinal tract as a mixed µ-opioid receptor agonist and δ-opioid receptor antagonist.

Radiation with or without antiandrogen therapy in recurrent prostate cancer.

Salvage radiation therapy is often necessary in men who have undergone radical prostatectomy and have evidence of prostate-cancer recurrence signaled by a persistently or recurrently elevated prostate-specific antigen (PSA) level.

Load more